Table 3.

Main Characteristics of the Analyzed Trials

Study	Patient Population	Treatment (N)	CR (n; %)	PR (n; %)	OR (n; %)	Criteria
Czuczman et al [4]: Prospective; Single treatment group; Intent to treat trial	N-40; 18 years and older with CD 20+ follicular lymphoma	R-CHOP N = 40	22; 55%	16; 40%	38; 95%	Table 1
Hiddemann W et al. [5]: Prospective, randomized, non-crossover, open label multicenter phase 3 trial	N = 428; 18 years and older with untreated advanced stage follicular lymphoma	R-CHOP (N = 223) vs. CHOP (N = 205)	44; 20% 35; 17%	170; 77% 150; 73%	214; 96% 185; 90%	IWG[13]
Domingo-Domenech et al. [6]: Prospective, non-randomized, non-crossover, open label multicenter phase 2 trial	N = 16; 18 to 70 years age with CD 20+ follicular lymphoma	R-CHOP (N = 16)	12; 75%	2; 13%	14; 88%	IWG [13]
Marcus R et al. [7]: Prospective, randomized, non-crossover trial	N = 321; 18 years or older, untreated CD 20+ follicular lymphoma	R-CVP (N = 162) vs. CVP (N = 159)	66; 41% 16; 11%	65; 40% 74; 47%	131; 81% 90; 57%	IWG[13]